Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aventis Nasacort HFA approved

Executive Summary

FDA clears Aventis'Nasacort HFA (triamcinolone acetonide) April 7 for nasal symptoms of seasonal and perennial allergic rhinitis for patients six years old and older. The drug is the first FDA-approved HFA nasal steroid; Aventis markets Nasacort AQ, the aqueous solution of triamcinolone, in a non-CFC metered-dose pump spray...

You may also be interested in...

GSK Flovent HFA approved

GlaxoSmithKline's CFC-free version of Flovent (fluticasone) for the treatment of asthma as prophylactic therapy in adults and adolescents 12 years and older clears FDA May 14. The drug is the second HFA nasal steroid to be approved after Aventis' Nasacort HFA inhaler for allergic rhinitis was cleared in April (1"The Pink Sheet" April 12, 2004, In Brief). A proposed rule on CFC-containing products is near publication (2"The Pink Sheet" April 26, 2004, In Brief)...

J&J’s Consumer Health Product Sales Slump In Comparison A Year After COVID-19 Stockpiling

Worldwide consumer health sales in January-March period were down 3.3% to $3.5bn with results off 7.4% to $1.6bn in the US and up 0.5% to $1.9bn internationally. However, excluding “COVID-19 comparison” in the year-ago period, the consumer health segment grew low-single-digits.

Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals

ANDA approval rates have remained steady, while submission rates dropped compared to prior years.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts